Core Insights - Impact BioMedical Inc. has acquired Celios®, an air purification technology company, in an all-equity transaction valued at approximately $1.15 million, aligning with its roll-up strategy to enhance its portfolio and generate immediate revenue [1][3] - Celios® offers advanced air purification capabilities with patents ensuring exclusivity through 2043, providing "virtually clean room" air quality through innovative filter technology [2][4] - The acquisition is a significant milestone for Impact BioMedical, reinforcing its commitment to health and wellness solutions while maintaining a strong cash position to support growth [3] Company Overview - Impact BioMedical Inc. focuses on discovering, developing, and patenting unique technologies in biopharmaceuticals and consumer healthcare, collaborating with external partners for research and development [5] - Celios® is dedicated to improving indoor air quality through patented filtration solutions that are efficient and portable, meeting high standards of cleanliness and safety [4]
Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"